Healthcare
Innate Pharma S.A.(IPHYF)
Live Price
Offline$1.65
+0.00% today
1Y Change
-15.38%
Window
Jun 25, 2025 β Jun 23, 2026
- Market Cap
- $110.00M
- Revenue Growth
- -77.9%
- EPS Growth
- +9.8%
- Dividend Yield
- 0.0%
Coverage: 249 bars Β· Jun 25, 2025 β Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Innate Pharma S.A. (IPHYF) is a Healthcare stock with a market cap of $110.00M and listed on OTC. The stock last traded around $1.65 and down 15.4% across the available one-year price window (Jun 25, 2025 β Jun 23, 2026). Baseline metrics include revenue growth of -77.9%, EPS growth of +9.8%, a dividend yield of 0.0%. What stands out right now is revenue -77.9%, EPS +9.8%, free cash flow -625.6% with operating margin -2058.0% and ROIC -155.5%. Valuation already assumes a fairly strong business story at price/sales 40.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines IPHYF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-77.9% vs +7.6% peer median
Operating Margin
Below sector median
-2058.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -77.9% and EPS is at +9.8%, with operating margin around -2058.0%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 17, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +16.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | β | +50.0% | +50.0% | +10.0% |
2025 Sep 17, 2025 | +12.4% | +0.0% | +0.0% | +0.0% |
2025 May 12, 2025 | -19.6% | +0.0% | +0.0% | -32.8% |
Benchmark Edge
IPHYF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IPHYF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IPHYF Max Drawdown
-36.29%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IPHYF and SPY.
Company Overview
Innate Pharma S.A.
Other OTC
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sΓ©zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
- Leadership
- Jonathan E. Dickinson
- IPO Date
- Jun 9, 2015
- Employees
- 181
- Street Address
- 117, Avenue de Luminy
- Mailing
- Marseille, 13009
- Region
- Marseille, FR
- Reporting Currency
- USD
- Investor Line
- 33 4 30 30 30 30
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 40.4
- Price/Book
- β
Growth
- Revenue
- -77.9%
- EPS
- +9.8%
- Free Cash Flow
- -625.6%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -2058.0%
- Net Margin
- -1764.5%
- ROE
- 593.9%
- ROIC
- -155.5%
Balance Sheet
- Debt/Equity
- β
- Current Ratio
- 1.27
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.